Redesigning Glaxo

摘要

When GlaxoSmithKline Plc bought cancer-treatment maker Tesaro for $5.1 billion last year, skeptics panned the deal, and the stock tumbled. On July 15 a key medicine acquired in the transaction yielded positive results, a small victory in Chief Executive Officer Emma Walmsley's bid to overhaul the British drugmaker.Seeking to catch rivals in the race to produce blockbuster drugs-and silence critics who see Glaxo as a lumbering giant-Big Pharma's first female CEO is engineering a radical shake-up, taking a different path than Bristol-Myers Squibb, Takeda Pharmaceutical, and AbbVie, which are reinventing themselves with megadeals.